Literature DB >> 17018694

Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons.

Simon Akerman1, Philip R Holland, Peter J Goadsby.   

Abstract

Migraine is a common and disabling neurological disorder that involves activation or the perception of activation of the trigeminovascular system. Cannabinoid (CB) receptors are present in brain and have been suggested to be antinociceptive. Here we determined the effect of cannabinoid receptor activation on neurons with trigeminovascular nociceptive input in the rat. Neurons in the trigeminocervical complex (TCC) were studied using extracellular electrophysiological techniques. Responses to both dural electrical stimulation and cutaneous facial receptive field activation of the ophthalmic division of the trigeminal nerve and the effect of cannabinoid agonists and antagonists were studied. Nonselective CB receptor activation with R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2, 3-de]-1,4-benzoxazin-yl]-(1-naphthalenyl) (WIN55,212; 1 mg kg(-1)) inhibited neuronal responses to A-(by 52%) and C-fiber (by 44%) afferents, an effect blocked by the CB(1) receptor antagonist SR141716 [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; 3 mg kg(-1)] but not the CB2 receptor antagonist AM630 (6-iodopravadoline; 3 mg kg(-1)). Anandamide (10 mg kg(-1)) was able to inhibit both A- and C-fiber-elicited TCC firing, only after transient receptor potential vanilloid 1 receptor inhibition. Activation of cannabinoid receptors had no effect on cutaneous receptive fields when recorded from TCC neurons. The data show that manipulation of CB1 receptors can affect the responses of trigeminal neurons with A- and C-fiber inputs from the dura mater. This may be a direct effect on neurons in the TCC itself or an effect in discrete areas of the brain that innervate these neurons. The data suggest that CB receptors may have therapeutic potential in migraine, cluster headache, or other primary headaches, although the potential hazards of psychoactive side effects that accompany cannabinoid treatments may be complex to overcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018694     DOI: 10.1124/jpet.106.106971

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats.

Authors:  Marek Zubrzycki; Anna Janecka; Andreas Liebold; Mechthild Ziegler; Maria Zubrzycka
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

2.  Endocannabinoids in the brainstem modulate dural trigeminovascular nociceptive traffic via CB1 and "triptan" receptors: implications in migraine.

Authors:  Simon Akerman; Philip R Holland; Michele P Lasalandra; Peter J Goadsby
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

3.  Phytomedicines in the Treatment of Migraine.

Authors:  Thilinie Rajapakse; William Jeptha Davenport
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 4.  Licit and illicit drug use in cluster headache.

Authors:  Amelie Govare; Elizabeth Leroux
Journal:  Curr Pain Headache Rep       Date:  2014-05

Review 5.  Cannabinoid control of neurogenic inflammation.

Authors:  Meagan McKenna; Jason J McDougall
Journal:  Br J Pharmacol       Date:  2020-08-13       Impact factor: 8.739

6.  Anti-migraine effect of ∆9-tetrahydrocannabinol in the female rat.

Authors:  Ram Kandasamy; Cole T Dawson; Rebecca M Craft; Michael M Morgan
Journal:  Eur J Pharmacol       Date:  2017-10-28       Impact factor: 4.432

Review 7.  Does exercise make migraines worse and tension type headaches better?

Authors:  Nada Ahmad Hindiyeh; John Claude Krusz; Robert Paul Cowan
Journal:  Curr Pain Headache Rep       Date:  2013-12

Review 8.  Why does increased exercise decrease migraine?

Authors:  Andrew H Ahn
Journal:  Curr Pain Headache Rep       Date:  2013-12

9.  Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels.

Authors:  Cristiana Rossi; Luigi Alberto Pini; Maria Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  Eur J Clin Pharmacol       Date:  2007-11-15       Impact factor: 2.953

10.  Inhibitory effect of high-frequency greater occipital nerve electrical stimulation on trigeminovascular nociceptive processing in rats.

Authors:  Olga A Lyubashina; Sergey S Panteleev; Alexey Y Sokolov
Journal:  J Neural Transm (Vienna)       Date:  2016-09-27       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.